Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 75 versus PALLADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 75 versus PALLADONE.
DURAGESIC-75 vs PALLADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
None Documented
None Documented
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Category C
Category C
Opioid Analgesic
Opioid Analgesic